LLS Focuses on Molecular Drivers for Leukemia

Dr Lee Greenberger - LLS

Dr Lee Greenberger – LLS

Leukemia & Lymphoma Society Initiatives to Halt Early Stage Myeloid Blood Cancers

Fourth in ASH 2014 Series

by David Wallace

PV Reporter sits down with Dr Lee Greenberger, Chief Scientific Officer with LLS, to discuss initiatives to halt early stage myeloid blood cancers (MPNs & MDS).  

LLS has grants with Dana Farber to better understand what are the molecular events to control early disease, blocking full blown disease.  Identifying therapeutics that could be used that would be effective and safe without the harsh side effects is another goal.

LLS has a partnership with MPN Research Foundation to evaluate and review grants, expanding the ability of both organizations to do research.  Check out the audio interview below for more details.

Greenberger discusses the Importance of Immunotherapy

The following interview by Cure Magazine, at ASH 2014, highlights the evolving role of immunotherapy in blood cancers.

Take me back to ASH Series Coverage
About David Wallace

Founder of PV Reporter, a resource for Myeloproliferative Neoplasm (MPN) patients and caregivers. After being diagnosed with Polycythemia Vera (PV) in 2009, I utilized social media to connect with "informed patients" and develop a better understanding of emerging treatment options. My philosophy on patient care is straight forward - "educating the patient is essential, so the patient can guide their physician to meet his or her needs." PV Reporter is a comprehensive resource hub giving visitors vital tools to become "empowered patients."

error: Content is protected !